Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281010 | 0.93 | EGLN1 (0.37) | ALDH1A1SOAT1ADRA2AADRA1ATSHR | |
| SCHEMBL3868426 | 0.87 | SOAT1 (0.46) | ALDH1A1SOAT1 | |
| SCHEMBL154677 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SOAT1 | |
| SCHEMBL12487440 | 0.79 | ALOX15 (0.34) | SOAT1TSHR | |
| SCHEMBL25996755 | 0.76 | SMN1; SMN2 (0.32) | ALDH1A1TSHR | |
| SCHEMBL12296672 | 0.76 | NAAA (0.50) | ALDH1A1SOAT1ADRA2AADRA1ABLM | |
| SCHEMBL2587969 | 0.75 | ADRA2A (0.43) | ALDH1A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL4334244 | 0.73 | MGAM (0.46) | ADRA2AADRA1AMAPTBLMTSHR | |
| SCHEMBL28886791 | 0.72 | DGKA (0.47) | ALDH1A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL3822361 | 0.72 | THRB (0.32) | MAPTBLMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933288-B2 | Pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2005-08-23 | — | — | US | disclosed |
| US-20030216575-A1 | Novel pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003066633-A1 | NOVEL PYRANOSYL CYTOSINES: PHARMACEUTICAL FORMULATIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216575-A1 | Novel pyranosyl cytosines: pharmaceutical formulations and methods | RNGTT, NOP2, RNMT | ALDH1A1 3286/4885SOAT1 2836/4885ADRA2A 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.